Analysis of Bausch + Lomb Corporation's debt issues, Bausch Health Companies Inc.'s Q3 results, and strategies to overcome ...
Novartis reports positive Phase 3B results for Fabhalta in PNH patients, highlighting improved hemoglobin levels and ...
Novartis (NVS) announced positive topline results from APPULSE-PNH, a Phase IIIB study evaluating the efficacy and safety of twice-daily oral ...
Promising topline results from a phase 3B study show the efficacy and quality of life (QOL) improvements of iptacopan ...
Novartis today announced positive top-line results from APPULSE-PNH, a Phase IIIb study on the efficacy and safety of ...
Analyst Joseph Schwartz from Leerink Partners reiterated a Hold rating on PTC Therapeutics (PTCT – Research Report) and increased the price ...
Novartis’ Fabhalta improved hemoglobin levels in patients with a rare blood disorder who switched from anti-C5 therapies, ...
Novartis (NYSE:NVS) reported positive Phase 3b data from a study of its drug Fabhalta for the treatment of the rare blood ...
Veeva Europe president Chris Moore talks about the company’s new genAI-powered releases and its move from Salesforce to a ...
Local Spotlight: Managing high bad cholesterol. High bad cholesterol is a risk factor for a common type of heart disease, yet ...
Max to immediately begin process to provide humanitarian access for Fabhalta® (iptacopan) in collaboration with its network of partner hematologists across 53 countriesPeople living with the rare ...
One of the impacted factories, Dura Supreme in Statesville, opened last year. Dura Supreme started as a family-run business ...